| human | Q5 |
| P496 | ORCID iD | 0000-0002-3356-7199 |
| P108 | employer | Luigi Sacco Hospital | Q3886605 |
| P735 | given name | ??? | Q13137395 |
| ??? | Q13137395 | ||
| P106 | occupation | researcher | Q1650915 |
| P21 | sex or gender | female | Q6581072 |
| Q34341541 | 96 Week follow-up of HIV-infected patients in rescue with raltegravir plus optimized backbone regimens: a multicentre Italian experience |
| Q79359210 | Antiretroviral treatment and age-related comorbidities in a cohort of older HIV-infected patients |
| Q57997331 | Atherosclerosis is associated with multiple pathogenic mechanisms in HIV-infected antiretroviral-naive or treated individuals |
| Q83141994 | Atypical pharmacokinetics of atazanavir in an HIV-1-infected patient |
| Q33768015 | Clinical and genetic factors associated with kidney tubular dysfunction in a real-life single centre cohort of HIV-positive patients |
| Q68702409 | Clinical and histologic aspects of chronic delta hepatitis |
| Q85015733 | Co-administration of raltegravir reduces daily darunavir exposure in HIV-1 infected patients |
| Q36396149 | Comparison of the in vivo pharmacokinetics and in vitro dissolution of raltegravir in HIV patients receiving the drug by swallowing or by chewing |
| Q42207795 | Comparison of the pharmacokinetics of raltegravir given at 2 doses of 400 mg by swallowing versus one dose of 800 mg by chewing in healthy volunteers: a randomized, open-label, 2-period, single-dose, crossover phase 1 study |
| Q46843144 | Determinants of HIV-1 genotypic resistance to darunavir (TMC114) in a large Italian resistance database (Antiretroviral Resistance Cohort Analysis). |
| Q40652183 | Determinants of bone diseases in tenofovir-treated HIV patients. |
| Q40397896 | Dolutegravir plasma concentrations according to companion antiretroviral drug: unwanted drug interaction or desirable boosting effect? |
| Q41993024 | Effect of cobicistat on tenofovir disoproxil fumarate (TDF): what is true for TAF may also be true for TDF. |
| Q36900555 | Effectiveness, durability, and safety of darunavir/ritonavir in HIV-1-infected patients in routine clinical practice in Italy: a postauthorization noninterventional study |
| Q43035709 | Eligibility and feasibility of the treatment of chronic hepatitis C in a Cohort of Italian HIV-positive patients at a single HIV reference center. |
| Q44975061 | Factors associated with virological success with raltegravir-containing regimens and prevalence of raltegravir-resistance-associated mutations at failure in the ARCA database. |
| Q30710478 | Four years data of raltegravir-based salvage therapy in HIV-1-infected, treatment-experienced patients: the SALIR-E Study. |
| Q28552320 | HIV-1 A1 Subtype Epidemic in Italy Originated from Africa and Eastern Europe and Shows a High Frequency of Transmission Chains Involving Intravenous Drug Users |
| Q28481828 | HIV-1 subtype F1 epidemiological networks among Italian heterosexual males are associated with introduction events from South America |
| Q27026182 | HIV-HCV co-infection: epidemiology, pathogenesis and therapeutic implications |
| Q58279119 | High burden of transmitted HIV-1 drug resistance in Italian patients carrying F1 subtype |
| Q41932770 | Hydroxychloroquine drastically reduces immune activation in HIV-infected, antiretroviral therapy-treated immunologic nonresponders |
| Q53310922 | Immune activation, apoptosis, and Treg activity are associated with persistently reduced CD4+ T-cell counts during antiretroviral therapy. |
| Q51486190 | Inter- and intra-patient variability of raltegravir pharmacokinetics in HIV-1-infected subjects. |
| Q51502265 | Interpretation of genotypic resistance to predict darunavir/ritonavir failure in antiretroviral experienced patients. |
| Q51595257 | Limited sampling strategies for the estimation of raltegravir daily exposure in HIV-infected patients. |
| Q46105533 | Long-term follow-up of HIV-infected patients in salvage therapy with raltegravir plus optimized background regimens: a multicentre Italian experience |
| Q42635997 | Lopinavir/ritonavir treatment in HIV antiretroviral-experienced patients: evaluation of risk factors for liver enzyme elevation. |
| Q28535587 | Low body weight in females is a risk factor for increased tenofovir exposure and drug-related adverse events |
| Q37308894 | Maraviroc as intensification strategy in HIV-1 positive patients with deficient immunological response: an Italian randomized clinical trial |
| Q59252619 | Maraviroc intensification for HIV-1-positive immunological non-responders (INRs) despite virological suppression during HAART |
| Q28546430 | Metabolic and kidney disorders correlate with high atazanavir concentrations in HIV-infected patients: is it time to revise atazanavir dosages? |
| Q38440702 | No pol mutation is associated independently with the lack of immune recovery in patients infected with HIV and failing antiretroviral therapy |
| Q57107097 | Pandemic influenza vaccine in adult HIV-1-infected patients |
| Q42230363 | Phylogenetic analysis provides evidence of interactions between Italian heterosexual and South American homosexual males as the main source of national HIV-1 subtype C epidemics |
| Q44147061 | Post transfusion hepatitis: comparison between homologous and autologous blood transfusion |
| Q38914167 | Predictive factors of hyperlipidemia in HIV-infected subjects receiving lopinavir/ritonavir. |
| Q38914178 | Predictive factors of lopinavir/ritonavir discontinuation for drug-related toxicity: results from a cohort of 416 multi-experienced HIV-infected individuals. |
| Q58812109 | Prevalence and factors associated with idiopathic hypercalciuria in HIV patients on combination antiretroviral therapy |
| Q43856664 | Prevalence of transmitted HIV-1 drug resistance in HIV-1-infected patients in Italy: evolution over 12 years and predictors. |
| Q44172302 | Risk factors for indinavir-related renal colic in HIV patients: predictive value of indinavir dose/body mass index. |
| Q58812104 | Secondary hyperparathyroidism in HIV patients |
| Q42279687 | Tenofovir plasma concentrations in post-menopausal versus pre-menopausal HIV-infected women |
| Q36102566 | Transmission of resistant HIV type 1 variants and epidemiological chains in Italian newly diagnosed individuals |
| Q43520841 | Update on emergence of HIV-1 resistance to antiretroviral drug classes in an Italian national database: 2007-2009. |
| Q44185379 | Virologic failure in an HIV-infected woman given desogestrel for excessive menstrual bleeding. |
| Q38914190 | Virological success of lopinavir/ritonavir salvage regimen is affected by an increasing number of lopinavir/ritonavir-related mutations. |
| Q40552597 | When food can make the difference: The case of elvitegravir-based co-formulation |
| Q58812120 | cART Durability and Causes for Treatment Switching or Discontinuation in HIV-Positive Patients Older Than 50 Years of Age |
Search more.